https://wwwnc.cdc.gov/eid/article/26/12/20-3334-f1

Link to Figure 1

- Both mild and severe patients had higher IgG and IgM levels than the control group without Covid-19. (Figure 1)
- IgM levels were overall higher in severe patients than mild. 
- However, IgM levels decreased over time in severe patients but not in mild. (Figure 1)
- IgG levels increased over time in both mild and severe patients, but severe patients developed increased levels earlier on than mild patients. (Figure 1)


Georgetown University

The goal of this study was to characterize the immune response and antibody production between mild and severe Covid-19 patients, a control group with no Covid-19 infection, and a group of patients recovered from illness in March and April. 
- Methods
- Results and conclusions

Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA

Hu WT, Howell JC, Ozturk T, et al. Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020 [published online ahead of print, 2020 Aug 28]. Emerg Infect Dis. 2020;
doi:10.3201/eid2612.203334

Results and Discussions 

In a study investigating antibody profiles in patients from Atlanta, Georgia, researchers measured immunoglobulin G (IgG) and immunoglobulin M (IgM) levels over time in 28 patients hospitalized for severe COVID-19, 15 patients with mild COVID-19, control participants, and 116 individuals with illnesses in March and April 2020. To accomplish this, the researchers developed and validated three distinct assays: one targeting the receptor-binding protein of the spike protein subunit S1 to measure IgG levels, another targeting the whole S1 protein to measure IgM levels, and a third targeting an envelope protein to also measure IgM levels.

Learn Before

Related

Learn After